Tezepelumab

Tezepelumab
	Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)[1]
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	TSLP
Clinical data
Other names	MEDI9929, AMG 157
Routes of; administration	Subcutaneous injection
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
CAS Number	1572943-04-4;
ChemSpider	none;
UNII	RJ1IW3B4QX;
KEGG	D11771;
Chemical and physical data
Formula	C6400H9844N1732O1992S52
Molar mass	144590.40 g·mol−1

Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma[2][3] and atopic dermatitis.[4][5] It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.[6]

This drug is being developed in collaboration by MedImmune, LLC and Amgen.

It is in Phase III trials as of October 2018.[7]

Structural studies by X-ray crystallography showed that Tezepelumab competes against a critical part of the TSLPR binding site on TSLP.[1]

References

Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.
Marone G, Spadaro G, Braile M, Poto R, Criscuolo G, Pahima H, et al. (November 2019). "Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma". Expert Opinion on Investigational Drugs. 28 (11): 931–940. doi:10.1080/13543784.2019.1672657. PMID 31549891.
Matera MG, Rogliani P, Calzetta L, Cazzola M (February 2020). "TSLP Inhibitors for Asthma: Current Status and Future Prospects". Drugs. doi:10.1007/s40265-020-01273-4. PMID 32078149.
"Statement On A Nonproprietary Name Adopted By The USAN Council - Tezepelumab" (PDF). American Medical Association. 30 December 2014.
World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
"Tezepelumab granted Breakthrough Therapy Designation by US FDA". AstraZeneca Press Release. 7 September 2018.
"Studies found for: Tezepelumab". ClinicalTrials.Gov. National Library of Medicine, National Institutes of Health, U.S. Department of Health and Human Services.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[:0-1] Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.

[pmid31549891-2] Marone G, Spadaro G, Braile M, Poto R, Criscuolo G, Pahima H, et al. (November 2019). "Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma". Expert Opinion on Investigational Drugs. 28 (11): 931–940. doi:10.1080/13543784.2019.1672657. PMID 31549891.

[pmid32078149-3] Matera MG, Rogliani P, Calzetta L, Cazzola M (February 2020). "TSLP Inhibitors for Asthma: Current Status and Future Prospects". Drugs. doi:10.1007/s40265-020-01273-4. PMID 32078149.

[4] "Statement On A Nonproprietary Name Adopted By The USAN Council - Tezepelumab" (PDF). American Medical Association. 30 December 2014.

[5] World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).

[6] "Tezepelumab granted Breakthrough Therapy Designation by US FDA". AstraZeneca Press Release. 7 September 2018.

[7] "Studies found for: Tezepelumab". ClinicalTrials.Gov. National Library of Medicine, National Institutes of Health, U.S. Department of Health and Human Services.